ストックスクリーナーアプリを入手
4.3076
3.61%
-0.1224
前日終値:
$4.43
開ける：
$4.26
24時間の取引高:
61,330
Relative Volume:
0.09
時価総額：
$469.02M
収益：
-
当期純損益:
$-299.80M
株価収益率:
-0.3554
EPS:
-12.1221
ネットキャッシュフロー:
$-217.49M
1週間 パフォーマンス:
-17.25%
1か月 パフォーマンス:
-30.91%
6か月 パフォーマンス:
-1.39%
1年 パフォーマンス:
-50.46%
1日の値動き範囲:
$4.24
$4.44
1週間の範囲:
$4.24
$5.19
52週間の値動き範囲:
$3.36
$8.885
Acelyrin Inc Stock (SLRN) Company Profile
SLRN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| SLRN | 4.295 | 469.02M | 0 | -299.80M | -217.49M | -12.12 |
| VRTX | 447.00 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.05 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.23 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.40 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.75 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-07-08 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-08 | 開始されました | Citigroup | Neutral |
| 2023-09-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-09-05 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-30 | 開始されました | Jefferies | Buy |
| 2023-05-30 | 開始されました | Morgan Stanley | Overweight |
| 2023-05-30 | 開始されました | Piper Sandler | Overweight |
| 2023-05-30 | 開始されました | TD Cowen | Outperform |
すべてを表示
Acelyrin Inc (SLRN) 最新ニュース
HC Wainwright Issues Positive Estimate for Acelyrin Earnings - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Q3 2024 Earnings Call Transcript - Insider Monkey
TD Cowen maintains Buy rating on Acelyrin shares By Investing.com - Investing.com Canada
Acelyrin discloses ValenzaBio acquisition financials - Investing.com India
TD Cowen maintains Buy rating on Acelyrin shares - Investing.com
T. Rowe Price Investment Management, Inc. Reduces Stake in Acely - GuruFocus.com
Earnings call: Acelyrin focuses on TED treatment, eyes Phase 3 trials - Investing.com
Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ... By GuruFocus - Investing.com Canada
ACELYRIN, INC. Advances Key Drug Developments - TipRanks
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights - The Manila Times
ACELYRIN Reports $562M Cash Position, Advances Key Clinical Trials Amid Pipeline Focus | SLRN Stock News - StockTitan
(SLRN) Investment Analysis and Advice - Stock Traders Daily
Acelyrin (SLRN) Set to Announce Earnings on Wednesday - MarketBeat
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024 - The Manila Times
ACELYRIN Sets Q3 2024 Earnings Call: Immunology Pipeline Updates Coming Nov 13 | SLRN Stock News - StockTitan
Vanguard Group Inc's Strategic Reduction in Acelyrin Inc Shares - GuruFocus.com
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
(SLRN) Proactive Strategies - Stock Traders Daily
Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.17 Consensus PT from Analysts - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Short Interest Update - MarketBeat
The Manufacturers Life Insurance Company Acquires 4,163 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin (NASDAQ:SLRN) Trading Down 6.9%What's Next? - MarketBeat
(SLRN) Trading Advice - Stock Traders Daily
Acelyrin (NASDAQ:SLRN) Trading 4.8% Higher on Analyst Upgrade - MarketBeat
SLRNACELYRIN, INC. Latest Stock News & Market Updates - StockTitan
Wells Fargo & Company Boosts Acelyrin (NASDAQ:SLRN) Price Target to $15.00 - MarketBeat
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease - The Manila Times
Did Acelyrin Inc (SLRN) perform well in the last session? - US Post News
Acelyrin (NASDAQ:SLRN) Stock Price Down 2.4%Should You Sell? - MarketBeat
Acelyrin Inc (SLRN) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Up 5.9%Still a Buy? - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Millennium Management LLC Has $20.47 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Renaissance Technologies LLC Has $1.75 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
160,167 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Bought by Susquehanna Fundamental Investments LLC - Defense World
Susquehanna Fundamental Investments LLC Takes Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Recent Insider Activity Suggests Potential Gains for Acelyrin Inc (SLRN) - Knox Daily
Almitas Capital LLC Buys New Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Piper Sandler maintains Overweight rating on Acelyrin shares - Investing.com
Piper Sandler maintains Overweight rating on Acelyrin shares By Investing.com - Investing.com Australia
Acelyrin Inc [SLRN] Director makes an insider sale of 1 shares worth $7.0. - Knox Daily
Top investors say Acelyrin Inc (SLRN) ticks everything they need - SETE News
Acelyrin Insider Sellers Miss The Bus As Stock Jumps 12% - Simply Wall St
Can Acelyrin Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Down 5.4% - MarketBeat
How did Acelyrin Inc (SLRN) fare last session? - US Post News
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch (NASDAQ:SLRN) - Seeking Alpha
Acelyrin (NASDAQ:SLRN) Shares Gap Up to $4.60 - MarketBeat
Acelyrin stock spikes on upcoming presentation (NASDAQ:SLRN) - Seeking Alpha
Acelyrin announces positive results from Phase 3 trial of izokibep - TipRanks
Acelyrin Inc (SLRN) 財務データ
収益
当期純利益
現金流量
EPS
Acelyrin Inc (SLRN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lin Shao-Lee | Chief Executive Officer |
Apr 01 '24 |
Sale |
6.63 |
9,961 |
66,024 |
1,577,374 |
| Lin Shao-Lee | Chief Executive Officer |
Feb 20 '24 |
Sale |
7.60 |
15,701 |
119,403 |
1,587,335 |
| Lin Shao-Lee | Chief Executive Officer |
Jan 02 '24 |
Sale |
7.41 |
10,691 |
79,188 |
1,603,036 |
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):